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Abstract
Background: Gastrointestinal stromal tumors (GIST) of the stomach are the most frequent
followed by those of the intestinal tract, while colon and rectum represent rare sites. GIST of the
anal canal are extremely rare. They have been studied along with GIST of the rectum, as a single
entity, and along with them they represent 5% of GIST. GIST arising from the anal canal account
for only 2%–8% of the anorectal GIST. Thus anal GIST must be considered an exceptional case.
Case presentation: A 78-year-old man was referred to our Institution for an anal mass, in
absence of any symptom. The patient was treated by local excision. An histological diagnosis of a
low grade GIST was made. No further treatment was necessary. No local recurrence of distant
metastases were found at follow-up.
Conclusion: At the moment, only ten cases of c-kit positive anal GIST are reported in the
literature. These few data are not sufficient to establish a widely accepted approach for this
neoplasia.
We recommend to perform an initial local excision, to define the risk of aggressive behavior and 
the resection margins and proceed to a more aggressive treatment, if the GIST belongs to high or 
very high risk group. The role of adjuvant therapy is still uncertain. Although inhibitors of tyrosine-
kinase receptor needs further studies before their routine use, their role in case of distant or local 
recurrence has been accepted. Patients' close follow up is mandatory to disclose as soon as possible 
local recurrences or metastases.
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Background
Gastrointestinal stromal tumors (GIST) represent the
most frequent mesenchymal neoplasm of the GI tract. As
reported by Nilsson et al., epidemiological data virtually
are non existent regarding the true incidence and preva-
lence of GIST[1]. This is due to the previous lack of well
defined pathologic criteria for GIST, varying nomencla-
ture for GIST over the past few decades, and the finding
that nearly 60% of all GIST have been diagnosed as
benign tumors or tumors of uncertain malignant poten-
tial, thus they are not reported to national cancer regis-
tries[1]. Therefore, Nilsson et al. analyzed the incidence
and prevalence of GIST in a defined population, in a prov-
ince of western Sweden. In that region the annual inci-
dence of clinically detected GIST was estimated 14.5 per
million inhabitants and the prevalence was 22.2 per mil-
lion for very low risk GIST, 51.9 per million for low risk,
24.2 per million for intermediate risk, 22.2 per million for
high risk and 8.7 per million for malignant GIST[1].
GIST are defined as mesenchymal neoplasm expressing
KIT protein, driven by KIT or PDGFRα (platelet derived
growth factor alpha) mutations[2]. They are regarded as
derived from interstitial cells of Cajal (ICC). ICC are pace-
maker cells that regulates peristalsis and have immu-
nophenotypic and ultrastructural features of both smooth
muscle and neural differentiation in varying degrees. ICC
are KIT positive cells. Activation of KIT  by mutations,
causes Cajal cell proliferation and GIST[3].
Most gastrointestinal stromal tumor (GIST) develop in
the stomach (50–60%), followed by small intestine (30–
40%), colon (7%) and esophagus (1%). Anal canal repre-
sents an extremely rare site of GIST[4]. Due to the rarity of
both rectal and anal GIST, just a few data exist about their
single incidence. They are often classified as anorectal
stromal tumors representing the 5% of all GIST[4,5]. We
present a case of anal GIST, treated by local excision, in
order to discuss diagnosis, surgical treatment and adju-
vant therapy of these rare lesions.
Case presentation
A 78-year-old man was referred to our Institution for the
presence of an anal mass accidentally discovered during a
routine physical exam. Past medical history was signifi-
cant for cancer of the right lung, treated with right pneu-
monectomy 1 year before. Routine blood test were within
normal limits as well as common neoplastic markers. The
rectal exam showed a well defined mass on the left-ante-
rior aspect of the anal canal, beginning at 1 cm from anal
verge and extending cranially for about 4 cm. Endoanal
ultrasonography confirmed the presence of a 4 × 2 cm
mass in the thickness of the sphincteric muscles (Fig 1 and
2). Total body CT scan confirmed the presence of the mass
and did not show any lymph node enlargement in the
proximity or distant metastases. The mass appeared cir-
cumscribed and not infiltrating the surrounding tissues
(Fig. 3).
The patient was brought to the operating room, placed in
jack-knife position, and a local excision was carried out,
resecting just a small amount of fibers of the anal sphinc-
ter. This has been possible since the mass was well capsu-
lated and not firmly adherent to the surrounding
structures. Gross pathological examination showed a 3.5
× 2 × 1.2 cm fibrous-elastic mass. Histological examina-
tion showed a proliferation of densely packed spindle
Endoanal ultrasonography (transverse plain) shows the mass  (*) located along the left anterior aspect of the anal canal Figure 2
Endoanal ultrasonography (transverse plain) shows the mass 
(*) located along the left anterior aspect of the anal canal.
Endoanal ultrasonography (longitudinal plain) shows a bilo- bate, circumscribed 4 × 2 cm mass Figure 1
Endoanal ultrasonography (longitudinal plain) shows a bilo-
bate, circumscribed 4 × 2 cm mass.World Journal of Surgical Oncology 2007, 5:20 http://www.wjso.com/content/5/1/20
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cells, with prominent nuclear palisading (Fig. 4). Nuclear
atypia was absent and mitotic count was of 4 mitosis/
50HPF. Neoplastic cells showed diffuse and marked cyto-
plasmic positivity for KIT protein and CD34 in the major-
ity of cells (Fig. 5). Neoplastic cells were negative for
desmin that stained residual smooth muscle fibers of
bowel wall at the margins of the neoplasm. A diagnosis of
GIST, with low risk aggressive behavior was made (Table
1)[6], therefore no further treatment was necessary.
Postoperative course was uneventful. No implications on
anal continence were observed and the patient was dis-
charged on postoperative day 3. The patient underwent
follow up at 6 and at 12 months, and rectal ultrasonogra-
phy as well as CT scan did not show local recurrence or
distant spread.
Discussion
GIST are the most common mesenchymal neoplasms of
the digestive tract. They are found more often in the stom-
ach (60–70%) and less frequently in the small intestine
(30%), while both the rectum and anus are extremely rare
locations with an incidence of 5% of all gastrointestinal
stromal tumors [4]; indeed anal GIST is a rarity represent-
ing only the 3% of all anorectal mesenchymal tumors [7].
Mutational status of c-KIT and PDGFRα genes are the
basis for the diagnosis of this neoplasia, an it represents
the criteria for surgical therapy, expected chemotherapy
response and clinical outcomes. In fact, most of GIST
express c-KIT [8,9]. The KIT protein (or CD117 antigen), a
proto-oncogene, is a transmembrane tyrosine kinase
receptor for a growth factor termed stem cell factor (SCF).
Mutations of KIT gene causes constitutional activation of
the kinase ligand-independent [3]. In a small percentage
of cases a mutations in another tyrosine-kinase receptor
(PDGFRα) has been demonstrated. Inhibitor of tyrosine-
kinase receptor as imatinib mesylate (STI-571, Gleevec;
Novartis, Switzerland), represents the target therapy for
local or distant recurrence after surgical resection in
GIST[10,11]. The effect of tyrosine-kinase inhibitor are
affected by the exon mutations on KIT gene. Several stud-
KIT staining in GIST Figure 5
KIT staining in GIST. Cytoplasmic and perinuclear strongly 
positive tumour cells (×200).
CT scan shows the mass (*) along the left anterior aspect of  the anal canal Figure 3
CT scan shows the mass (*) along the left anterior aspect of 
the anal canal.
Fascicular arrangement of spindle cells with prominent  nuclear palisading and perinuclear cytoplasmic vacuoles  (×200) Figure 4
Fascicular arrangement of spindle cells with prominent 
nuclear palisading and perinuclear cytoplasmic vacuoles 
(×200).World Journal of Surgical Oncology 2007, 5:20 http://www.wjso.com/content/5/1/20
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ies reported clinical evidence of tumor response to imat-
inib, ranging from 12 % and 70% in cases of exon 9 and
exon 11 mutations of the C-KIT  gene respectively[12].
Although prediction of clinical outcome has been exten-
sively studied [13-15] the widely accepted criteria to pre-
dict the malignancy of GIST are the mitotic activity (>5
mitotic figures per 50 × high power field) and the tumor
size (>5 cm) (Table 1)[6]. But also in case of a very low
risk lesion, Fletcher et al. stressed its spreading potential,
admitting the presence of still unknown malignant fac-
tors[6]. Factors as mucosal invasion and tumor necrosis
have found to be related to increased risk of aggressive
behavior, but their clinic value remains uncertain. It
should be noted that the guidelines proposed by Fletcher
et al. recommend categorizing GIST into risk categories,
emphasizing that no lesion can be definitely labeled as
benign[6,16].
In addition the GIST susceptibility to metastasize via
bloodstream, and to relapse as local recurrence, makes the
surgical treatment controversial regarding the extent of
resection. Authors who treated rectal GIST by an abdomi-
noperineal resection reported a low local recurrence, with
no improvement in incidence of distant metastases and
overall survival rate[13].
We recommend, in case of anal GIST, to perform the less
extensive excision that achieves the essential R0 resection
and defines the aggressive risk grade, followed by a Miles
abdominoperineal resection when histopathological
diagnosis displays a tumor size >5 cm together with
Tan et al reported a total of 16 cases of anal GIST in the
literature from 1966 to 2001[17]. However, the Authors
enrolled in their review all cases in literature, without dis-
tinguishing GIST from the other mesenchymal stromal
tumors and describing symptoms, treatment and out-
comes of anorectal stromal tumors all together[5,7,18-
22]. We reviewed the literature focusing only on c-kit pos-
itive anal GIST. We found three published papers, describ-
ing a total of nine c-kit positive anal GIST. Miettinen et
Tworek did not focus on anal GIST features, dealing with
both rectal and anal GIST as an homogeneous group,
while Vidarsdottir reports an anal GIST, previously diag-
nosed as anal sarcoma in 1987[5,7,23]. Therefore, at this
moment, only ten cases of c-kit positive anal GIST are
reported in the literature.
Conclusion
At the moment, only ten cases of c-kit positive anal GIST
are reported in the literature. These few data are not suffi-
cient to establish a widely accepted approach for this neo-
plasia.
We recommend to perform an initial local excision, to
define the risk of aggressive behavior and the involvement
of the resection margins. The margin positivity (R1)
should indicate the need of a more aggressive treatment,
such as, in selected cases, abdomino-perineal resection,
especially if the tumor belongs to high or very high risk
group. The role of adjuvant therapy is still uncertain.
Although inhibitors of tyrosine-kinase receptor needs fur-
ther studies before using them routinely as adjuvant ther-
apy, their role in case of distant or local recurrence has
been accepted. Patients' close follow up is mandatory to
disclose as soon as possible local recurrences or metas-
tases.
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Table 1: Proposed approach for defining risk of aggressive 
behaviour in GIST [9]
Size Mitotic Count
Very low risk < 2 cm < 5/50 HPF
Low risk 2–5 cm < 5/50 HPF
Intermediate risk < 5 cm 6–10/50 HPF
5–10 cm < 5/50 HPF
High risk > 5 cm > 5/50 HPF
> 10 cm Any mitotic rate
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